China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic systems and high intensity focused ultrasound products, today announced that it has completed the development of 10 new enhanced chemiluminescence immunoassay ("ECLIA") infertility diagnostic reagents, increasing the Company's reagent kit offering to a total of 72. China Medical expects to introduce these new reagents in July 2007.

These reagents are designed to measure a number of different antibodies that affect reproduction and may be used to analyze immunological factors that cause infertility.

The National Population and Family Planning Commission of China estimates that there were over 300 million women of child-bearing age in China in 2006. Approximately 10% of couples in China face infertility problems, which typically refer to situations where couples fail to conceive following two years of attempts. Immunological factors are generally responsible for approximately 30% of infertility problems. Immunological tests provide a way to analyze the possible causes of infertility that arise from the immune system. Timely and accurate diagnosis is a crucial step in determining the appropriate therapy for infertility, where subsequent therapies are made possible to couples planning for pregnancy.

Source:佚名